(Q34182324)

31 July 2017

1 reference

title

Tiludronate. A new treatment for an old ailment: Paget's disease of bone (English)

1 reference

31 July 2017

Morales-Piga A

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

1

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

157-170

1 reference

Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.157

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.157

Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.157

Effects of 1-hydroxyethylidene-1,1 bisphosphonate and (chloro-4 phenyl) thiomethylene bisphosphonic acid (SR 41319) on the mononuclear cell factor-mediated release of neutral proteinases by articular chondrocytes and synovial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.157

A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.157

Hypercalcemia induced with an arotinoid in thyroparathyroidectomized rats. New model to study bone resorption in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.157

Comparison of the efficacy and bioequivalence of two oral formulations of tiludronate in the treatment of Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.157

Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.157

Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.157

Paget's disease of bone treated with a five day course of oral tiludronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.157

Mineralisation defects with pamidronate therapy for Paget's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.157

Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.1.157

21 January 2018

Identifiers

DOI

10.1517/14656566.1.1.157

1 reference

31 July 2017

1 reference